Closantel retinal toxicity: Recovery from severe vision loss after corticosteroid therapy.
RETINA
Systemic drug retinal toxicity
anatomy/biochemistry/physiology
inner retinal/vitreoretinal dystrophies
retina – medical therapies
retinal pathology / research
Journal
European journal of ophthalmology
ISSN: 1724-6016
Titre abrégé: Eur J Ophthalmol
Pays: United States
ID NLM: 9110772
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
medline:
10
7
2023
pubmed:
9
7
2022
entrez:
8
7
2022
Statut:
ppublish
Résumé
To present a relatively rare case of retinal toxicity and consequent severe vision loss due to Closantel ingestion. A 37-year-old female presented with sudden painless decrease vision in both eyes. She had no previous history of medical disease and denied any trauma. The patient had accidentally ingested Closantel a few days prior to presentation. Closantel is a veterinary anti-helminthic drug used mainly in livestock. Best corrected visual acuity (BCVA) at presentation was 20/200 bilaterally. There was no relative afferent pupillary defect (RAPD) and red saturation test was normal. Macular optical coherence tomography (OCT) revealed disruption in the outer retinal layer and ellipsoid zone in both eyes. A diagnosis of retinal toxicity due to Closantel was made and the patient was started on 1 mg/kg oral prednisolone acetate. On the 45th day after presentation, her BCVA had improved to 20/20 bilaterally. Closantel is a potentially toxic drug causing destruction of the neurosensory retina and visual disturbances. We suggest eye-care personnel awareness regarding the risk of Closantel-induced retinal toxicity and prompt treatment with systemic steroids should be considered.
Identifiants
pubmed: 35799445
doi: 10.1177/11206721221111887
doi:
Substances chimiques
closantel
EUL532EI54
Salicylanilides
0
Adrenal Cortex Hormones
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM